In the News
Branden Moriarity harnesses the power of genome engineering, where scientists reprogram DNA, to develop innovative immunotherapy approaches for treating highly lethal forms of cancer. Moriarity’s work, combined with that of his colleagues, was the foundation for B-MoGen Biotechnologies Inc., a University startup company launched in 2016. He currently serves as B-MoGen’s chief scientific officer. Moriarity, a Masonic Cancer Center researcher, was a winner of the 2019 Early Innovator Award.
Doctors at the University of Minnesota are the first in the country to use a breakthrough brain cancer treatment.
Author: Kent Erdahl
Published: 11:13 PM CST February 14, 2019
Updated: 11:16 PM CST February 14, 2019
Large animal models can be important translational steps between basic research in rodents and clinical care in humans. Ever thought about a pig?
Featuring Christopher Moertel, MD.
Hannah Carlin, a fourth-year student studying microbiology, doesn't recall much of her cancer treatment — granted, she was 16 months old at the time of her diagnosis.
But her mother, Beth Heinz, certainly does.
"You're not guaranteed anything in life. You're not guaranteed a lifetime with your children," Heinz said to The Minnesota Daily.
Monteris Medical studies changes in patients who have faced mortality.
By Joe Carlson Star Tribune
German citizen Steffen Rhode spent a year in high school in 1998 studying as a foreign-exchange student in Fosston, Minn. He returned 20 years later with a new hole in his head.